Developing new antiviral treatments for childhood respiratory viruses
Official title: Broad spectrum inhibitors of paramyxovirus envelope proteins
Funded at Columbia University Health Sciences · NIH-10893937 · Data updated 2026-11-12
This study is working on new inhalable treatments to help kids who get sick from human parainfluenza viruses, which can cause serious breathing problems like croup and bronchiolitis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $780,280 |
| NIH project number | 5R01AI175362-02 |
| Project ID | NIH-10893937 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years who are at risk for infections caused by human parainfluenza viruses.
✕Less likely to help
Patients who are older than 11 years or those with other unrelated respiratory conditions may not benefit from this research.
What this research studies
This research focuses on creating effective antiviral treatments for human parainfluenza viruses, which are responsible for serious respiratory illnesses in children, such as croup and bronchiolitis. The team will explore innovative methods to inhibit viral entry into cells by designing new compounds that can be administered through inhalation. By using advanced techniques to modify existing antiviral agents, they aim to enhance their effectiveness and stability. The research includes laboratory experiments to test these new treatments against various strains of respiratory viruses.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antiviral medications that significantly reduce the severity and incidence of respiratory infections in children.
How similar studies have gone: Previous research has shown promise in developing antiviral agents targeting similar viral entry mechanisms, indicating potential for success in this novel approach.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Moscona, Anne — Columbia University Health Sciences
- Study coordinator: Moscona, Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.